Comparing Two Heart Medicines for Fast, Irregular Heartbeat (Atrial Fibrillation)

Sponsor
Muhammad Ali Javed
Study ID
NCT07706075
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Atrial Fibrillation (AF)
  • Atrial Fibrillation With Rapid Ventricular Response

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Verapamil Hydrochloride — DRUG
    Intravenous verapamil administered as an initial 5 mg dose over 2 minutes, with an additional 5 mg dose permitted after 15 minutes if target heart rate not achieved, up to a cumulative maximum of 10 mg.
  • Metoprolol tartrate — DRUG
    Intravenous metoprolol tartrate administered as an initial 5 mg dose over 2 minutes, with up to two additional 5 mg doses at 5-minute intervals if target heart rate not achieved, up to a cumulative maximum of 15 mg.

Study Details

The goal of this clinical trial is to learn whether intravenous verapamil or intravenous metoprolol controls heart rate more effectively in adult patients who arrive at the emergency department with atrial fibrillation and a fast heart rate (rapid ventricular response), but who are otherwise medically stable. Atrial fibrillation with a rapid heart rate is a common emergency, and doctors currently choose between these two standard medicines based on personal preference rather than strong local evidence, since there is limited research on this comparison in Pakistani patients. The main questions this study aims to answer are: Does a higher proportion of patients reach a target heart rate of less than 110 beats per minute within 30 minutes with verapamil compared to metoprolol? Which medicine controls the heart rate faster, on average? Are there differences in side effects (such as low blood pressure, slow heart rate, or breathing problems) between the two medicines? Researchers will compare a group of patients receiving verapamil to a group receiving metoprolol to see if one medicine controls the heart rate faster and more safely than the other. Participants will: 1. Receive either verapamil or metoprolol through an IV, with the dose given according to standard protocols 2. Have their heart rate, blood pressure, and oxygen levels monitored continuously for 30 minutes after the medicine is given 3. Be observed for any side effects during this monitoring period Both medicines used in this study are already standard, guideline-recommended treatments for this condition, so participation will not change or delay the medical care patients would normally receive.

Key Dates

First listed
Jul 15, 2026
Start date
Jan 1, 2027
Status verified
Jul 2026
Primary completion
Jul 1, 2027
Completion
Aug 1, 2027

Study Design

Enrollment
120 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Verapamil group
    Participants received intravenous verapamil, initial dose 5 mg over 2 minutes; if target heart rate (\<110 bpm) not achieved within 15 minutes, an additional 5 mg IV dose given, to a cumulative maximum of 10 mg.
  • Active Comparator: Metoprolol group
    Participants received intravenous metoprolol tartrate, initial dose 5 mg over 2 minutes; if target heart rate (\<110 bpm) not achieved within 5 minutes, up to two additional 5 mg IV doses given at 5-minute intervals, to a cumulative maximum of 15 mg.

Primary Outcome Measure

Proportion of Participants Achieving Target Heart Rate Control Within 30 Minutes [ Time Frame: 30 minutes after study drug administration ]

Central Contacts

Related Studies